dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hodkinson, Brendan P. |
dc.contributor.author | Schaffer, Michael |
dc.contributor.author | Brody, Joshua D. |
dc.contributor.author | Carpio Segura, Cecilia Carmen |
dc.contributor.author | Ben-Yehuda, Dina |
dc.contributor.author | Jurczak, Wojciech |
dc.date.accessioned | 2021-06-14T12:41:37Z |
dc.date.available | 2021-06-14T12:41:37Z |
dc.date.issued | 2021-01 |
dc.identifier.citation | Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, et al. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter’s transformation. Transl Oncol. 2021 Jan;14(1):100977. |
dc.identifier.issn | 1936-5233 |
dc.identifier.uri | https://hdl.handle.net/11351/6069 |
dc.description | Biomarcadors; Ibrutinib; Limfoma no hodgkin |
dc.description.sponsorship | Sponsored by Janssen Research & Development, LLC. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Translational Oncology;14(1) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Limfomes |
dc.subject | Medicaments antineoplàstics |
dc.subject | Marcadors bioquímics |
dc.subject.mesh | Lymphoma |
dc.subject.mesh | Drug Therapy, Combination |
dc.subject.mesh | Biomarkers |
dc.title | Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.tranon.2020.100977 |
dc.subject.decs | linfoma |
dc.subject.decs | farmacoterapia combinada |
dc.subject.decs | biomarcadores |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S1936523320304691 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Hodkinson BP, Schaffer M] Oncology Translational Research, Janssen Research & Development, Spring House, PA 19477, United States. [Brody JD] Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States. [Jurczak W] Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, 31-115, Poland. [Carpio C] Servei d’Hematologia i hemoteràpia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ben-Yehuda D] Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel |
dc.identifier.pmid | 33395752 |
dc.identifier.wos | 000604582000003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |